Literature DB >> 27111811

Resting functional connectivity in social anxiety disorder and the effect of pharmacotherapy.

Alexander Doruyter1, Christine Lochner2, Gerhard P Jordaan3, Dan J Stein4, Patrick Dupont5, James M Warwick6.   

Abstract

Neuroimaging research has reported differences in resting-state functional connectivity (RFC) between social anxiety disorder (SAD) patients and healthy controls (HCs). Limited research has examined the effect of treatment on RFC in SAD. We performed a study to identify differences in RFC between SAD and HC groups, and to investigate the effect of pharmacotherapy on RFC in SAD. Seed-based RFC analysis was performed on technetium-99m hexamethylpropylene amine oxime (Tc-99m HMPAO) SPECT scans using a cross-subject approach in SPM-12. Seeds were chosen to represent regions in a recently published network model of SAD. A second-level regression analysis was performed to further characterize the underlying relationships identified in the group contrasts. Twenty-three SAD participants were included, of which 18 underwent follow-up measures after an 8-week course of citalopram or moclobemide. Fifteen healthy control (HC) scans were included. SAD participants at baseline demonstrated several significant connectivity disturbances consistent with the existing network model as well as one previously unreported finding (increased connectivity between cerebellum and posterior cingulate cortex). After therapy, the SAD group demonstrated significant increases in connectivity with dorsal anterior cingulate cortex which may explain therapy-induced modifications in how SAD sufferers interpret emotions in others and improvements in self-related and emotional processing.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anterior cingulate; Pharmacologic effects; Phobia, social; SPECT

Mesh:

Substances:

Year:  2016        PMID: 27111811     DOI: 10.1016/j.pscychresns.2016.04.009

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  6 in total

Review 1.  Resting-state neuroimaging in social anxiety disorder: a systematic review.

Authors:  Simone Mizzi; Mangor Pedersen; Valentina Lorenzetti; Markus Heinrichs; Izelle Labuschagne
Journal:  Mol Psychiatry       Date:  2021-05-25       Impact factor: 15.992

Review 2.  Neuroimaging Predictors and Mechanisms of Treatment Response in Social Anxiety Disorder: an Overview of the Amygdala.

Authors:  Heide Klumpp; Jacklynn M Fitzgerald
Journal:  Curr Psychiatry Rep       Date:  2018-08-28       Impact factor: 8.081

3.  Cerebellar and basal ganglia motor network predicts trait depression and hyperactivity.

Authors:  T Bryan Jackson; Jessica A Bernard
Journal:  Front Behav Neurosci       Date:  2022-09-16       Impact factor: 3.617

4.  Clinical significance of increased cerebellar default-mode network connectivity in resting-state patients with drug-naive somatization disorder.

Authors:  Houliang Wang; Wenbin Guo; Feng Liu; Jindong Chen; Renrong Wu; Zhikun Zhang; Miaoyu Yu; Lehua Li; Jingping Zhao
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

5.  Evaluation of drug effects on cerebral blood flow and glucose uptake in un-anesthetized and un-stimulated rats: application of free-moving apparatus enabling to keep rats free during PET/SPECT tracer injection and uptake.

Authors:  Taku Sugita; Yusuke Kondo; Seigo Ishino; Ikuo Mori; Takashi Horiguchi; Mikako Ogawa; Yasuhiro Magata
Journal:  Nucl Med Commun       Date:  2018-08       Impact factor: 1.690

Review 6.  ENIGMA-anxiety working group: Rationale for and organization of large-scale neuroimaging studies of anxiety disorders.

Authors:  Janna Marie Bas-Hoogendam; Nynke A Groenewold; Moji Aghajani; Gabrielle F Freitag; Anita Harrewijn; Kevin Hilbert; Neda Jahanshad; Sophia I Thomopoulos; Paul M Thompson; Dick J Veltman; Anderson M Winkler; Ulrike Lueken; Daniel S Pine; Nic J A van der Wee; Dan J Stein
Journal:  Hum Brain Mapp       Date:  2020-07-03       Impact factor: 5.399

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.